The US deflazacort market is closely linked to the treatment landscape for Duchenne muscular dystrophy (DMD), where corticosteroid therapy plays an important role in maintaining muscle function. Deflazacort received its first US approval in 2017 for DMD and is now available in both tablet and oral suspension formulations. The expansion of generic availability and additional manufacturers is...